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Abstract 
A method for the direct introduction of Aib-Pro into peptides on solid phase was 
developed. The Aib-Pro unit was introduced by means of the ‘azirine/oxazolone method’ 
using allyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate as the synthon. After the reaction of 
the resin-bound amino or peptide acid with allyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate, 
the allyl protecting group of the resulting extended peptide could be removed by a mild Pd0-
promoted procedure. Cleavage of the peptide from the resin was performed with UV-light at 
352 nm and yielded C-terminal protected peptides. The method found a successful application 
in the syntheses of different Aib-Pro containing peptaibol segments. Furthermore, a protected 
derivative of the peptide antibiotic Trichovirin I 1B was prepared by segment condensation. 
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1. Introduction 
2H-Azirin-3-amines are highly-strained systems with versatile reactivity.1 One very 
interesting and useful reaction is their application in peptide synthesis. In the 
‘azirine/oxazolone method’, 2H-azirin-3-amines such as 1 or 2, are used as synthons for the 
introduction of sterically demanding α,α-disubstituted α-amino acids into peptides.1–3 Thus, 
the reaction of 2H-azirin-3-amines, e.g., the α-aminoisobutyric acid (Aib) synthon 1a, with 
amino or peptide acids leads to peptide amides, the terminal amide bonds of which can be 
hydrolyzed selectively to give extended peptide acids. In solution-phase chemistry, the 
‘azirine/oxazolone method’ has proven to be successful for the introduction of a variety of 
sterically demanding α,α-disubstituted α-amino acids into oligopeptides,4–13 
endothiopeptides,14–16 cyclic peptides,17–18 and cyclic depsipeptides.19–23 
 
Formula Collection 
 
Recently, we adapted the ‘azirine/oxazolone method’ to solid-phase conditions, in order to 
additionally benefit from their advantages,24 e.g., the rapid access to peptides without the need 
for the isolation of the sometimes cumbersome peptide acid intermediates. In this method, the 
growing peptide was attached through a carbamate linker to a [4-
(hydroxymethyl)phenyl]acetamidomethyl (PAM) polystyrene resin (3) (Scheme 1). After 
deprotection of tBu ester 4a, resin-bound amino acid 4b was treated with a solution of 1a. It is 
worth mentioning that unconsumed 1a could easily be recovered and re-used. The terminal 
amide 5a was selectively hydrolyzed with 3M HCl in THF/H2O to provide the resin-bound 
peptide acid 5b. Further extension of the peptide chain could be achieved either with a tBu 
protected amino acid and a coupling reagent or with 1a. Cleavage of the peptide from the 
resin was achieved with HBr (33%) in acetic acid, and yielded the tripeptide 6. In a recent 
paper, we showed that the method is not restricted to the Aib synthon 1a, and that it was 
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successfully extended  to the 1-aminocyclopentane-1-carboxylic acid synthon 1b, the 4-
amino-3,4,5,6-tetrahydro-2H-pyran-4-carboxylic acid synthon 1c, and the α-
methylphenylalanine synthon 1d.25 
 
Scheme 1 
 
Peptaibols are linear, amphiphilic oligopeptides from fungal sources with a high proportion 
of α,α-disubstituted α-amino acids, primarily, Aib.26–27 Peptaibols show antibiotic properties 
due to self-association in lipid membranes forming ion channels.28 Several peptaibols, or 
segments thereof, were synthesized by means of the ‘azirine/oxazolone method’.4,8–13 The 2H-
azirin-3-amine 2a played an important role in these syntheses, since 2a allowed the direct 
introduction of the frequently present, but relatively acid labile, Aib-Pro unit.9 Unexpectedly, 
the use of 2a on solid phase was not successful (vide infra). 
Herein we report a method for the introduction of the Aib-Pro unit into peptides on solid 
phase, using a photolabile linker and a new Aib-Pro synthon (2b), which was especially 
developed for this purpose.29 
 
 
2. Results and Discussion 
The most obvious approach to the introduction of the Aib-Pro unit was the use of synthon 
2a in analogy to the method outlined in Scheme 1. In doing so, the resin-bound amino acid 4b 
was treated with a solution of 2a, and the resulting resin-bound tripeptide methyl ester 7 was 
saponified with LiOH in a mixture of THF, MeOH, and H2O (Scheme 2). After coupling with 
H-Val-OtBu by using PyBOP as the coupling reagent, the peptide was cleaved from the resin 
with HBr (33%) in acetic acid to give H-Ala-Aib-Pro-Val-OH (9) in 20% yield. In order to 
guarantee proper swelling of the resin during the saponification, the experiment was repeated 
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with a Tentagel resin. However, the yield of 21% was still conspicuously lower in comparison 
with the introduction of the synthons 1a–d (37–50%). The problem was recognized, when the 
synthesis of the model peptide H-Ala-Aib-Pro-Leu-Aib-Val-OH (on Tentagel resin) and the 
peptaibol segment (A8–A14 of Trichovirin Ia) H-Val-Aib-Gly-Aib-Aib-Pro-Leu-OH (on 
polystyrene resin) failed. Only peptide fragments, which are caused by Aib-Pro fissions, were 
detected. The analysis of the fragments revealed that the cleavage of the Aib-Pro amide bond 
occurred during the HBr-promoted cleavage of the peptide from the resin, and not during the 
hydrolysis of the terminal amide, which was necessary after the incorporation of 1a. 
 
Scheme 2 
 
Thus, a linker was required which can be cleaved under milder conditions, but is still stable 
in TFA (50%) and HCl (3M). Some years ago, Kunz introduced a Pd0-labile allyl linker for 
the synthesis of peptide acids.30 Therefore, we synthesized 2-{[(Z)-4-
(triisopropylsilyloxy)but-2-enyl]oxy}ethanoic acid31 and attached its carboxy group via an 
alanine spacer to an aminomethyl polystyrene resin.32 Additionally, (E)-7-hydroxyhept-5-
enoic acid was prepared,33 and its carboxy group was attached to an aminomethyl polystyrene 
resin. In both cases, the N-terminus of the first amino acid was immobilized through a 
carbamate group to the resin (in the first case after removing the TIPS-protecting group with 
TFA), and the resin-bound peptides 6 and 9 were synthesized analogously to the ‘PAM/HBr-
strategy’. Cleavage from the resin was performed with Pd(Ph3P)4 and PhSiH3 in 
DMSO/CH2Cl2, but the desired peptides could only be obtained in low yield and after a 
painstaking purification of the Pd-containing crude product. 
In 1995, Holmes introduced a photolabile nitroveratryl linker and immobilized peptides by 
coupling their C-terminus to the resin.34–36 This photolinker is among the most effective ever 
described – it is stable to various chemical reactions, but can easily be cleaved with UV-light 
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with λ = 365 nm, a wavelength that does not affect aromatic amino acids such as Trp or Tyr. 
The corresponding photocleavable resin 10 (Scheme 3) is commercially available from 
Novabiochem. 
With the aim of testing the stability under acidic conditions, N-(4,5-dimethoxy-2-
nitrobenzyloxy)carbonyl-L-alanine tert-butyl ester (NVOC-Ala-OtBu) was prepared by 
reaction of 4,5-dimethoxy-2-nitrobenzyl alcohol and COCl2 in THF, and subsequently with 
H-Ala-OtBu · HCl under Schotten-Baumann conditions to give NVOC-Ala-OtBu, which was 
then subjected to acidic conditions. Apart from tBu hydrolysis, neither in TFA (50%), nor in 
HCl (3M) was cleavage or decomposition of the linker observed. Hence, the chloroformate of 
the photocleavable resin 10 was reacted with H-Ala-OtBu. Deprotection of the tBu ester 11 
with TFA afforded the resin-bound amino acid 12, which was treated with a solution of 1a. 
Selective hydrolysis of the terminal amide of the resin-bound dipeptide 13 with 3M HCl 
afforded the resin-bound peptide acid 14, which was coupled with H-Phe-OtBu. Cleavage of 
the peptide from the resin was performed with UV-light (16 × 8 W, λmax = 352 nm) in 
MeCN/H2O, but the initial yields were disappointing. Most probably, the remaining 
nitrosoaldehyde functionalized resin captured the peptide 15 via imine-formation with its 
amino group.37 This assumption was supported by 1H-NMR experiments: the formyl signal of 
methyl 4-[(4-formyl-2-methoxy-5-nitrophenyl)oxy]butanoate disappeared within 20 min on 
reaction with isopropylamine, and a new signal at 8.65 ppm, typical for imines, appeared. To 
overcome the interception of the peptide, the cleavage from the resin was performed in a 
solution of semicarbazide hydrochloride in THF/MeOH.37 Although 15 was now obtained in 
much better yield (ca. 30–40%), its purity was unsatisfactory. Therefore, the general 
procedures had to be slightly modified again. The reaction time for the tBu ester hydrolysis 
was extended to 60 min to avoid the previously detected H-Ala-Phe-OtBu side product. 
Moreover, the synthesis was carried out on a polystyrene  instead of a Tentagel resin. The use 
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of Tentagel resin suffered from (poly)ethylene glycol loss. Finally, model peptide 15 was 
prepared in high purity and in 33% yield (after prep. HPLC, based on resin loading). 
 
Scheme 3 
 
After having established the protocol for the use of Aib synthon 1a, the preparation of Aib-
Pro containing peptides was attempted. But when dipeptide synthon 2a was used to 
incorporate the Aib-Pro unit, the experiment failed again (Scheme 3). During the 
saponification of resin-bound methyl ester 16 to give 17, we observed a considerable 
darkening of the resin, which prevented the subsequent photo-induced cleavage of the peptide 
from the resin. 
This issue was addressed by the synthesis of the new Aib-Pro synthons allyl N-(2,2-
dimethyl-2H-azirin-3-yl)-L-prolinate (2b) and phenacyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-
prolinate (2c), which contain easily removable carboxy-protecting groups.29 The resin-bound 
amino acid 12 was reacted with a solution of 2c, and the resulting resin-bound phenacyl ester 
was treated with tetrabutylammonium fluoride. Again, considerable darkening of the resin 
was observed. On the other hand, the allyl protecting group of resin-bound peptide 19, 
obtained from the reaction of 12 and 2b, was smoothly removed with Pd(Ph3P)4 and PhSiH338 
in CH2Cl2 to give the resin-bound peptide acid 17 (Scheme 4). The latter was then coupled 
with H-Phe-OtBu and PyBOP as the coupling reagent affording the corresponding resin-
bound tetrapeptide. Cleavage from the resin was achieved with UV-light (16 × 8 W, λmax = 
352 nm) in a solution of semicarbazide hydrochloride in THF/MeOH and gave H-Ala-Aib-
Pro-Phe-OtBu (18) in high purity and in 35% yield (after prep. HPLC, based on resin 
loading). 
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Scheme 4 
 
To evaluate the described protocol for the introduction of the Aib-Pro motif into peptides, 
the preparation of some peptaibol segments was attempted. The heptapeptide H-Val-Aib-Gly-
Aib-Aib-Pro-Leu-OtBu (20, A8–A14 of Trichovirin Ia; Table 1), whose synthesis failed with 
the ‘PAM/HBr-strategy’ (see above), was prepared in 42% yield using the photocleavable 
resin 10, the Aib synthon 1a, and the allyl-protected Aib-Pro synthon 2b. Gly and Leu were 
introduced with PyBOP as the coupling reagent. Analogously, the syntheses of the hexa- and 
octapeptides H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (21, A1–A6 of Trichovirin I 1B) and 
H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (22, A7–A14 of Trichovirin I 1B) were carried 
out. Sequence 21 was chosen to evaluate the introduction of non-aliphatic amino acids, while 
in the synthesis of 22, an Aib-Pro unit had to be installed prior to an Aib-residue and another 
Aib-Pro unit. Both peptides were prepared on the photocleavable resin 10 using the Aib 
synthon 1a and the allyl protected Aib-Pro synthon 2b. All other amino acids were introduced 
with PyBOP as the coupling reagent. The side chain of Asn was not protected, while the 
hydroxy group of the serine side chain was masked as benzyl ether, a protecting group which 
is orthogonal to the tBu protecting group. The peptides were obtained in 34% yield each (after 
prep. HPLC, based on resin loading), which is comparable to that of tetrapeptide 18 and 
therefore indicating a good linker stability. 
 
Table 1 
 
In contrast to the ‘PAM/HBr-strategy’ (Scheme 1), the use of the photolinker allows the 
preparation of tBu-protected peptides, which, in turn, offers the possibility of segment 
condensations. For that purpose, the C-terminal tBu-protected peptides had to be transformed 
into N-terminal protected peptides. Therefore, the tBu-protected peptide 18 was reacted with 
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N-(benzyloxycarbonyloxy)succinimid (Z-ONSu), and the corresponding tBu protecting group 
was hydrolyzed to give the N-protected peptide 23 (Scheme 5). 
 
Scheme 5 
 
Analogously, the heptapeptide 21 (A1–A6 of Trichovirin I 1B) was transformed into the N-
protected peptide 24 (Scheme 6). Due to steric hindrance of Aib, the reaction time for the 
introduction of the Z-protecting group was extended to 8 h. However, the transformation was 
not complete, and 21 (20%) was partially recovered. The hydrolysis of the corresponding tBu 
ester with TFA was accompanied by partial cleavage of the Aib-Pro amide bond. Most 
probably, the extent of this side reaction could be reduced by shortening the reaction time 
(HPLC/MS indicates complete deprotection already after 20 min). Finally, 24 was coupled 
with 22 (A7–A14 of Trichovirin I 1B) and TBTU as the coupling reagent, and protected 
Trichovirin I 1B (Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-
OtBu; 25) was obtained in 73% yield (Scheme 5).39 
 
Scheme 6 
 
 
3. Conclusions 
A method for the direct introduction of Aib-Pro into peptides via ‘azirine coupling’ on 
solid phase was developed. The protocol is based on a photocleavable resin (10) and the Aib-
Pro synthon 2b. After the coupling of the resin-bound peptide acid with 2b, the allyl 
protecting group of the extended peptide was removed by a mild Pd0-promoted procedure. In 
contrast to the previously described ‘PAM/HBr-strategy’, this protocol allows the isolation of 
peptides with a protected C-terminus. The method found a successful application in the 
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syntheses of different Aib-Pro containing peptaibol segments. A subsequent segment 
condensation led to the Trichovirin I 1B derivative 25, an oligopeptide containing three Aib-
Pro units and two additional Aib residues. 
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4. Experimental Part 
4.1. General 
Unless otherwise noted, materials were obtained from commercial suppliers and were used 
without further purification. Aminomethyl polystyrene resin (1% divinylbenzene, 100–200 
mesh, loading 1.14 mmol/g) and aminomethyl Tentagel resin (90 µm, loading 0.28 mmol/g) 
from Rapp Polymere (Rapp Polymere, Tübingen, Germany). Hydroxymethyl-photolinker AM 
resin (10) (polystyrene, 1% divinylbenzene, 100–200 mesh, loading 0.75 mmol/g) from 
Novabiochem (Calbiochem-Novabiochem, Läufelfingen, Switzerland). N,2,2-Trimethyl-N-
phenyl-2H-azirin-3-amine (1a) was synthesized according to the method of Villalgordo and 
Heimgartner.40,41 Methyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-prolinate (2a), allyl N-(2,2-
dimethyl-2H-azirin-3-yl)-L-prolinate (2b) and phenacyl N-(2,2-dimethyl-2H-azirin-3-yl)-L-
prolinate (2c) were synthesized according to Ref. 9 (2a) and Ref. 29 (2b, 2c), respectively. H-
Ser(OBn)-OtBu was prepared by treatment of Fmoc-Ser(OBn)-OH with tert-butyl 
trichloroacetamidate and removal of Fmoc with Et2NH. The 1H-NMR spectra of H-Ser(OBn)-
OtBu was in accordance with the data given in Ref. 42. Reaction vessels for solid phase 
synthesis: Single fritted (20 µm) PE reservoir (15 ml) (Separtis, Grenzach-Wyhlen, Germany) 
were wrapped with aluminum foil and used on an Advanced ChemTech PLS 4 × 6 Shaker 
(Advanced ChemTech, Inc., Louisville, KY, USA) with a selfmade adapter. The original 
Advanced ChemTech reaction vessels were used for reactions with COCl2. Photolysis was 
performed in a quartz tube (13.5 cm, 13 mm i.d.). Irradiation with circulary arranged sterilAir 
BLB8 lamps (16 × 8 W, λmax = 352 nm) (sterilAir AG, Weinfelden, Switzerland). High-
performance liquid chromatography (HPLC): instrument: Waters 600E multisolvent delivery 
system equipped with a Waters 996 PDA (Waters, Milford, CA, USA); column: Interchim 
Uptisphere WOD C18, 300 Å, 10 µm, 250 × 21.2 mm (Interchim, Montluçon, France); 
eluents: A = H2O/TFA (0.1%), B = MeCN/TFA (0.1%); flow rate: 10 ml/min; various 
gradients. Column chromatography (CC): Silica gel C-560 from Chemie Uetikon (CU Chemie 
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Uetikon GmbH, Uetikon, Switzerland). IR Spectra: Perkin-Elmer, Spectrum one FT-IR 
spectrophotometer (Perkin-Elmer, Wellesley, MA, USA), absorptions in cm–1. NMR Spectra: 
Bruker AV-600 (Bruker Biospin, Karlsruhe, Germany). Chemical shifts in ppm relative to 
tetramethylsilane as internal standard. 2D-NMR experiments were performed for assignment 
of the signals. The integer n in Xaan corresponds to the position of the amino acid within the 
peptide, but is only given if the amino acid was present more than once in the peptide and if 
the NMR signal could be assigned unambigously. HPLC/MS: The system consists of a Rheos 
2000 pump, a Rheos CPS-LC degasser (Flux Instruments, Basel, Switzerland) and a Thermo 
Finnigan Surveyor photo-diode array detector (Thermo Finnigan, San Jose, CA, USA). The 
HPLC-system is equipped with a HTS PAL autosampler (CTC Analytics, Zwingen, 
Switzerland) and connected to a Thermo Finnigan MSQ linear quadrupole instrument. 
Interchim Uptisphere C18-ODB, 120 Å, 3 µm, 50 × 2.0 mm column; eluents: A = H2O, B = 
MeCN, C = HCOOH (1%) in H2O; flow rate: 0.2 ml/min, gradient (A:B:C): 0.0–15.0 min: 
87:3:10–40:50:10. MS: Bruker ESQUIRE-LC quadrupole instrument (Bruker Daltonik 
GmbH, Bremen, Germany) or Finnigan TSQ-700 triple quadrupole instrument (Finnigan 
MAT, San Jose, CA, USA). Direct infusion ESI-MS were performed with a syringe infusion 
pump at a flow rate of 5 µl/min. 
 
4.2. Abbreviations 
Aib: α-aminoisobutyric acid; DIPEA: N,N-diisopropylethylamine; HOBt: 1-
hydroxybenzotriazole; PyBOP: (1H-benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate; TBTU: O-(1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
tetrafluoroborat; TFA: trifluoroacetic acid; TIPS: triisopropylsilane; Z: benzyloxycarbonyl; Z-
ONSu: N-[(benzyloxycarbonyl)oxy]succinimid. 
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4.3. General Procedures 1–7 (GP 1 – GP 7) 
GP 1: Attachment of the First Amino Acid. All manipulations were carried out under N2. 
Hydroxymethyl-photolinker AM resin was swollen in THF. After filtration, a solution of 
COCl2 (CAUTION) in toluene (ca. 20%, 10 equiv.) and THF (ca. 0.7 ml/100 mg resin) were 
added to the resin, which was agitated at rt for 2 h, then washed with THF (2×) and CH2Cl2 
(2×). In a separate vial, H-Xaa-OtBu · HCl (4 equiv.) was dissolved in DIPEA (8 equiv.) and 
CH2Cl2 (conc. of H-Xaa-OtBu · HCl = ca. 0.2M). This mixture was added to the resin and any 
ammonium salt that occured was removed by filtration. The resin was agitated at rt overnight, 
then washed with DMF (3×) and CH2Cl2 (3×). 
GP2: Removing the tBu Protecting Group. The resin was swollen in CH2Cl2. TFA in CH2Cl2 
(2 ml, 1×15 s, 25%; 2 ml, 1×60 min, 50%) and TIPS (5%, in each case) were added, and the 
resin was agitated at rt. Then, the resin was washed with CH2Cl2 (3×), DMF (2×) and CH2Cl2 
(3×). 
GP3: Coupling with 2H-Azirin-3-amines 1a, 2a and 2b. The corresponding resin was swollen 
in CH2Cl2. A solution of 2H-azirin-3-amine (4 equiv.) in CH2Cl2 (conc. of 2H-azirin-3-amine 
= ca. 0.2M) was added, the resin was agitated at rt overnight, and then washed with CH2Cl2 
(3×). Unconsumed 2H-azirin-3-amine could easily be recovered. 
GP 4: Hydrolysis of the Terminal Amide. The resin was swollen in THF. Aq. HCl (ca. 2 
ml/100 mg resin, 3M in THF/H2O, prepared from conc. HCl and THF) was added, and the 
resin was agitated at rt overnight, then washed with THF (3×), DMF (3×) and CH2Cl2 (3×). 
GP 5: Coupling with H-Xaa-OtBu · HCl. The resin was swollen in DMF. HOBt (6 equiv.) in 
DMF, PyBOP (4 equiv.) in DMF, H-Xaa-OtBu · HCl (4 equiv.) in DMF and DIPEA (12 
equiv.) were added (conc. of H-Xaa-OtBu . HCl = ca. 0.2M), the resin was agitated at rt, and 
then washed with DMF (3×) and CH2Cl2 (3×). 
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GP 6: Removal of the Allyl Protecting Group. The resin was dried i.v. All manipulations were 
carried out under Ar. The resin was swollen in CH2Cl2. A mixture of Pd(Ph3P)4 (0.3 equiv.) 
and PhSiH3 (20 equiv.) in CH2Cl2 (ca. 2 ml/100 mg resin) was added, the resin was agitated at 
rt for 1.5 h, and then washed with CH2Cl2 (3×), DMF, CH2Cl2 (2×), THF (1% H2O) (2×), 
THF (1×), MeOH and CH2Cl2 (2×). 
GP 7: Cleavage. The resin (ca. 0.075 mmol) was swollen in a solution of semicarbazide 
hydrochloride (24 mg) in MeOH/THF (2:1, 6 ml), and the mixture was degassed by bubbling 
Ar into the mixture. Under vigorous stirring, the resin was irradiated with 16 × 8 W (λmax = 
352 nm) for 2 h, then the supernatant solution was removed, and the irradiation process was 
repeated two times. Afterwards, the resin was washed with MeOH/THF (2:1, 3×). All 
solutions were combined, concentrated under reduced pressure, and the crude product was 
purified by means of HPLC. The purified product was lyophilized. 
 
4.4. Synthesis of Peptides 
4.4.1. H-Ala-Aib-Pro-Val-OH (9). Aminomethyl Tentagel resin (350 mg, 0.098 mmol) was 
swollen in DMF. 4-(hydroxymethyl)phenylacetic acid (33 mg, 0.199 mmol), DIPEA (103 µl, 
0.602 mmol) and PyBOP (104 mg, 0.200 mmol) in DMF (1.5 ml) were added, and the resin 
was agitated at rt for 30 min (negative Kaiser test), then washed with DMF (3×), CH2Cl2 (3×) 
and THF (3×). The resin was treated as described in GP 1, 2, and 3. Then, the resin was 
swollen in a mixture of THF (1 ml) and MeOH (0.7 ml), and LiOH · H2O (33 mg, 0.787 
mmol) in H2O (0.3 ml) was added. The resin was agitated at rt overnight, washed with 
THF/MeOH/H2O (4:3:1, 3×), and DMF (3×). The resin was treated as described in GP 5 (2 
h), then swollen in CH2Cl2. HBr in AcOH (33%, 3 ml) and two drops of H2O were added, and 
the resin was agitated at rt for 4h. The resin was separated by filtration and washed with 
AcOH/CH2Cl2 (1:1, 3×) and MeCN/CH2Cl2 (1:1, 3×). The solvents were evaporated under 
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reduced pressure and the crude product was purified by means of HPLC. The purified product 
was lyophilized and yielded 9 (10 mg, 21%) as a colorless powder. IR (KBr): 3435s, 3271s, 
3068s, 2969s, 2882s, 1674vs, 1630vs, 1548s, 1472m, 1422s, 1369m, 1338w, 1310w, 1269m, 
1202vs, 1183vs, 1138vs, 1005w, 979w, 929w, 837w, 800w, 722m. 1H-NMR ((D6)DMSO, 
600 MHz): ca. 10.0–7.0 (br s, NH3(Ala)); 8.61 (s, NH(Aib)); 7.73 (d, J = 8.2 Hz, NH(Val)); 
4.42–4.41 (m, CH(α)(Pro)); 4.06–4.04 (m, CH(α)(Val)); 3.88–3.87 (m, CH(α)(Ala)); 3.57–
3.54, 3.38–3.34 (2m, CH2(δ)(Pro)); 2.04 (dsept., J = 6.6, 6.6 Hz, CH(β)(Val)); 1.88–1.83, 
1.81–1.76 (2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.37, 1.34 (2s, 2 Me(Aib)); 1.36 (d, J = 7.6 Hz, 
Me(Ala)); 0.90, 0.89 (2d, J = 6.8 Hz, 2 Me(Val)). 13C-NMR ((D6)DMSO, 150 MHz): 173.0 
(s, CO(Val)); 171.9 (s, CO(Pro)); 170.4 (s, CO(Aib)); 168.4 (s, CO(Ala)); 60.6 (d, 
CH(α)(Pro)); 57.2 (d, CH(α)(Val)); 56.0 (s, C(α)(Aib)); 47.9 (d, CH(α)(Ala)); 47.6 (t, 
CH2(δ)(Pro)); 29.9 (d, CH(β)(Val)); 27.9, 25.2 (2t, CH2(β)(Pro), CH2(γ)(Pro)); 24.9, 24.5 (2q, 
2 Me(Aib)); 19.1, 18.1 (2q, 2 Me(Val)); 17.3 (q, Me(Ala)). ESI-MS: 371 (100, [M+H]+), 215 
(34, [Pro-Val]+). 
 
4.4.2. H-Ala-Aib-Phe-OtBu (15). Aminomethyl polystyrene resin (62 mg, 0.071 mmol) was 
swollen in DMF. 4-[(4-Hydroxymethyl-2-methoxy-5-nitrophenyl)oxy]butanoic acid (40 mg, 
0.140 mmol), PyBOP (72 mg, 0.138 mmol) and DIPEA (72 µl, 0.421 mmol) in DMF (1.5 ml) 
were added, and the resin was agitated at rt for 30 min, then washed with DMF (3×), CH2Cl2 
(2×) and THF (2×). The resin was treated as described in GP 1, 2, 3, 4, 5 (overnight), and 7 to 
yield 15 (11.4 mg, 33%) as a colorless powder after prep. HPLC purification and 
lyophilization. IR (KBr): 3426s, 3399s, 3288s, 3065m, 3032m, 2983s, 2939s, 1724s, 1674vs, 
1549s, 1516s, 1457m, 1440m, 1393m, 1368s, 1324w, 1259s, 1204vs, 1180vs, 1156vs, 
1139vs, 1079w, 1030w, 1015w, 1003w, 948w, 929w, 881w, 839m, 800w, 754w, 739w, 
722m, 700m. 1H-NMR ((D6)DMSO, 600 MHz): 8.31 (s, NH(Aib)); 8.01 (br s, NH3(Ala)); 
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7.67 (d, J = 7.8 Hz, NH(Phe)); 7.29–7.19 (m, 5 arom. H); 4.34 (ddd, J = 8.2, 7.8, 6.4 Hz, 
CH(α)(Phe)); 3.84 (q, J = 6.9 Hz, CH(α)(Ala)); 3.02 (dd, J = 13.8, 6.4 Hz, 1 H of CH2(Phe)); 
2.95 (dd, J = 13.8, 8.2 Hz, 1 H of CH2(Phe)); 1.38, 1.37 (2s, 2 Me(Aib)); 1.33 (s, Me3C); 1.32 
(d, J = 7.3 Hz, Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 172.9 (s, CO(Aib)); 170.4 (s, 
CO(Phe)); 168.8 (s, CO(Ala)); 137.4 (s, arom. C); 129.2, 128.1, 126.4 (3d, 5 arom. CH); 80.7 
(s, Me3C); 56.3 (s, C(α)(Aib)); 54.2 (d, CH(α)(Phe)); 48.3 (d, CH(α)(Ala)); 36.8 (t, 
CH2(Phe)); 27.5 (q, Me3C); 24.7, 24.6 (2q, 2 Me(Aib)); 17.1 (q, Me(Ala)). ESI-MS: 378 (53, 
[M+H]+), 322 (100, [M–tBu]+). HPLC/MS: tR 10.3 min, m/z 378 (16, [M+H]+), 322 (100, [M–
tBu]+), 157 (27, [M–(Phe-OtBu)]+). 
 
4.4.3. H-Ala-Aib-Pro-Phe-OtBu (18). Hydroxymethyl-photolinker AM resin (101 mg, 0.075 
mmol) was treated as described in GP 1, 2, 3, 6, 5 (2 h), and 7 to yield 18 (15.6 mg, 35%) as a 
colorless powder after prep. HPLC purification and lyophilization. IR (KBr): 3428s, 3293s, 
3065s, 3032s, 2983s, 2940s, 1728s, 1674vs, 1548s, 1536s, 1499m, 1472m, 1456m, 1422m, 
1415m, 1395m, 1369m, 1258m, 1203vs, 1177vs, 1156vs, 1135vs, 1052w, 1029w, 1004w, 
928w, 879w, 836w, 800w, 740w, 721m, 701m. 1H-NMR ((D6)DMSO, 600 MHz): 8.65 (s, 
NH(Aib)); 8.08 (br s, NH3(Ala)); 7.91 (d, J = 7.4 Hz, NH(Phe)); 7.29–7.20 (m, 5 arom. H); 
4.33–4.31 (m, CH(α)(Pro)); 4.26 (ddd, J = 7.3, 7.3, 7.3 Hz, CH(α)(Phe)); 3.88–3.87 (m, 
CH(α)(Ala)); 3.52–3.50, 3.38–3.35 (2m, CH2(δ)(Pro)); 2.97–2.95 (m, CH2(Phe)); 1.86–1.76, 
1.69–1.67 (2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.36 (d, J = 7.1 Hz, Me(Ala)); 1.35, 1.34 (2s, 2 
Me(Aib)); 1.30 (s, Me3C). 13C-NMR ((D6)DMSO, 150 MHz): 171.7 (s, CO(Pro)); 170.4 (s, 
CO(Phe)); 170.3 (s, CO(Aib)); 168.3 (s, CO(Ala)); 137.3 (s, arom. C); 129.2, 128.0, 126.3 
(3d, 5 arom. CH); 80.3 (s, Me3C); 60.7 (d, CH(α)(Pro)); 55.9 (s, C(α)(Aib)); 54.2 (d, 
CH(α)(Phe)); 47.8 (d, CH(α)(Ala)); 47.5 (t, CH2(δ)(Pro)); 36.6 (t, CH2(Phe)); 27.9 (t, 
CH2(β)(Pro)); 27.4 (s, Me3C); 25.0 (t, CH2(γ)(Pro)); 24.7, 24.6 (2q, 2 Me(Aib)); 17.1 (q, 
  18 
Me(Ala)). ESI-MS: 497 (10, [M+Na]+), 475 (100, [M+H]+), 419 (17, [M–tBu]+), 319 (7, [M–
(Ala-Aib)]+). HPLC/MS: tR 9.9 min, m/z 497 (10, [M+Na]+), 475 (30, [M+H]+), 419 (24, [M–
tBu]+), 319 (32, [M–(Ala-Aib)]+), 263 (100, [M–(Ala-Aib)–tBu]+). 
 
4.4.4. H-Val-Aib-Gly-Aib-Aib-Pro-Leu-OtBu (20). Hydroxymethyl-photolinker AM resin 
(100 mg, 0.075 mmol) was treated as described in GP 1, 2, 3, 4, 5 (overnight), 2, 3, 4, 3, 6, 5 
(2 h), and 7 to yield 20 (25.7 mg, 42%) as a colorless powder after prep. HPLC purification 
and lyophilization. IR (KBr): 3433vs, 3317vs, 3063m, 2978s, 2939s, 2877m, 1725m, 1671vs, 
1543vs, 1537vs, 1469m, 1440m, 1416m, 1397m, 1384m, 1368m, 1333w, 1282m, 1248m, 
1203vs, 1178vs, 1146s, 1018w, 947w, 878w, 837w, 801w, 722w. 1H-NMR ((D6)DMSO, 600 
MHz): 8.82 (s, NH(Aib2)); 8.20 (s, NH(Gly)); 8.08 (br s, NH3(Val)); 7.81 (d, J = 8.1 Hz, 
NH(Leu)); 7.72 (s, NH(Aib4)); 7.43 (s, NH(Aib5)); 4.37–4.35 (m, CH(α)(Pro)); 4.11–4.07 (m, 
CH(α)(Leu)); 3.61–3.59 (m, CH(α)(Val), 1 H of CH2(Gly), 1 H of CH2(δ)(Pro)); 3.55–3.51 
(m, 1 H of CH2(Gly)); 3.43–3.39 (m, 1 H of CH2(δ)(Pro)); 2.12 (dsept., J = 6.7, 6.7 Hz, 
CH(β)(Val)); 2.02–1.98 (m, 1 H of CH2(β)(Pro)); 1.74–1.69 (m, 1 H of CH2(β)(Pro), 
CH2(γ)(Pro)); 1.63–1.57 (m, CH(γ)(Leu), 1 H of CH2(β)(Leu)); 1.51–1.45 (m, 1 H of 
CH2(β)(Leu)); 1.403, 1.398 (2s, 2 Me(Aib2), 2 Me(Aib4)); 1.38 (s, Me3C); 1.35, 1.33 (2s, 2 
Me(Aib5)); 0.96, 0.94 (2d, J = 7.0 Hz, 2 Me(Val)); 0.89, 0.82 (2d, J = 6.3 Hz, 2 Me(Leu)). 
13C-NMR ((D6)DMSO, 150 MHz): 174.6 (s, CO(Aib2)); 174.3 (s, CO(Aib4)); 171.7 (s, 
CO(Pro)); 171.1 (s, CO(Leu)); 171.0 (s, CO(Aib5)); 168.4 (s, CO(Gly)); 168.0 (s, CO(Val)); 
79.9 (s, Me3C); 60.8 (d, CH(α)(Pro)); 57.5 (d, CH(α)(Val)); 56.13 (s, C(α)(Aib4)); 56.09 (s, 
C(α)(Aib2)); 56.0 (s, C(α)(Aib5)); 50.9 (d, CH(α)(Leu)); 47.2 (t, CH2(δ)(Pro)); 43.8 (t, 
CH2(Gly)); 39.3 (t, CH2(β)(Leu)); 29.5 (d, CH(β)(Val)); 28.4 (t, CH2(β)(Pro)); 27.5 (q, 
Me3C); 25.8 (q, 1 Me of 2 Me(Aib4)); 25.6 (q, 1 Me of 2 Me(Aib2)); 25.2 (q, 1 Me of 2 
Me(Aib5)); 25.0 (t, CH2(γ)(Pro)); 24.5 (q, 1 Me of 2 Me(Aib4)); 24.2 (d, CH(γ)(Leu)); 24.0 (q, 
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1 Me of 2 Me(Aib5)); 23.7 (q, 1 Me of 2 Me(Aib2)); 22.7, 21.2 (2q, 2 Me(Leu)); 18.4, 17.5 
(2q, 2 Me(Val)). ESI-MS: 718 (17, [M+Na]+), 696 (100, [M+H]+). HPLC/MS: tR 11.5 min, 
m/z 696 (100, [M+H]+), 640 (27, [M–tBu]+), 412 (24, [M–(Pro-Leu-OtBu)]+), 339 (16). 
 
4.4.5. H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (21). Hydroxymethyl-photolinker AM resin 
(100 mg, 0.075 mmol) was treated as described in GP 1, 2, 5 (overnight), 2, 5 (90 min), 2, 3, 
6, 5 (90 min), and 7 to yield 21 (21.7 mg, 34%) as a colorless powder after prep. HPLC 
purification and lyophilization. IR (KBr): 3427s, 3301s, 3066m, 2979m, 2961m, 2938m, 
2875m, 1673vs, 1535s, 1470m, 1453m, 1424m, 1412m, 1369m, 1247m, 1203vs, 1182vs, 
1138vs, 837w, 800w, 742w, 722m, 700w. 1H-NMR ((D6)DMSO, 600 MHz): 8.39–8.37 (m, 
NH(Asn)); 8.17–8.13 (m, NH(Leu), NH3(Aib1), NH(Aib4)); 7.99 (d, J = 8.0 Hz, NH(Ser)); 
7.42–7.41 (m, 1 H of CONH2(Asn)); 7.36–7.32, 7.29–7.27 (2m, 5 arom. H); 6.98 (s, 1 H of 
CONH2(Asn)); 4.70 (ddd, J = 7.5, 7.5, 7.5 Hz, CH(α)(Asn)); 4.49, 4.53 (AB, J = 12.1 Hz, 
OCH2Ph(Ser)); 4.42–4.40 (m, CH(α)(Pro)); 4.36–4.33 (m, CH(α)(Ser)); 4.29–4.25 (m, 
CH(α)(Leu)); 3.72 (dd, J = 9.7, 5.8 Hz, 1 H of CH2(β)(Ser)); 3.65 (dd, J = 9.7, 4.4 Hz, 1 H of 
CH2(β)(Ser)); 3.46–3.44, 3.42–3.38 (2m, CH2(δ)(Pro)); 2.64–2.60, 2.43–2.39 (2m, 
CH2(β)(Asn)); 1.90–1.87, 1.77–1.72 (2m, CH2(β)(Pro), CH2(γ)(Pro)); 1.60–1.55 (m, 
CH(γ)(Leu)); 1.49–1.43 (m, CH2(β)(Leu)); 1.45, 1.43 (2s, 2 Me(Aib1)); 1.37 (s, Me3C); 1.34, 
1.30 (2s, 2 Me(Aib4)); 0.86, 0.80 (2d, J = 6.6 Hz, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 
MHz): 171.9 (s, CO(Pro)); 171.2 (s, CO(Leu), CONH2(Asn)); 171.1 (s, CO(Aib1)); 170.8 (s, 
CO(Aib4)); 170.3 (s, CO(Asn)); 169.0 (s, CO(Ser)); 137.9 (s, arom. C); 128.1, 127.5, 127.4 
(3d, 5 arom. CH); 80.5 (s, Me3C); 72.1 (t, OCH2Ph(Ser)); 69.3 (t, CH2(β)(Ser)); 60.5 (d, 
CH(α)(Pro)); 56.2 (s, C(α)(Aib1)); 55.6 (s, C(α)(Aib4)); 52.8 (d, CH(α)(Ser)); 50.8 (d, 
CH(α)(Leu)); 49.8 (d, CH(α)(Asn)); 47.3 (t, CH2(δ)(Pro)); 40.3 (t, CH2(β)(Leu)); 36.8 (t, 
CH2(β)(Asn)); 28.0 (t, CH2(β)(Pro)); 27.5 (q, Me3C); 25.0 (t, CH2(γ)(Pro)); 24.9, 24.7 (2q, 2 
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Me(Aib4)); 24.1 (d, CH(γ)(Leu)); 23.3, 23.1 (2q, 2 Me(Aib1)); 22.9, 21.3 (2q, 2 Me(Leu)). 
ESI-MS: 768 (100, [M+Na]+), 746 (48, [M+H]+), 712 (28, [M–tBu+Na]+), 622 (17). 
HPLC/MS: tR 12.4 min, m/z 746 (100, [M+H]+), 398 (34, [M–(Pro-Ser(OBn)-tBu)]+). 
 
 
4.4.6. H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (22). Hydroxymethyl-photolinker AM 
resin (100 mg, 0.075 mmol) was treated as described in GP 1, 2, 3, 6, 3, 4, 5 (overnight), 2, 3, 
6, 5 (2 h), and 7 to yield 22 (24.8 mg, 34%) as a colorless powder after prep. HPLC 
purification and lyophilization. IR (KBr): 3440vs, 3330sh, 3058m, 2961s, 2874m, 1724sh, 
1653vs, 1627vs, 1536vs, 1471s, 1451m, 1440m, 1416s, 1385m, 1368m, 1344w, 1249m, 
1241m, 1203vs, 1178vs, 1146s, 839w, 833w, 800w, 722w. 1H-NMR ((D6)DMSO, 600 MHz): 
9.00 (s, NH(Aib2)); 8.13 (br s, NH3(Val)); 7.77 (d, J = 7.8 Hz, NH(Leu8)); 7.72 (s, NH(Aib4)); 
7.69 (s, NH(Aib6)); 7.38 (d, J = 8.5 Hz, NH(Leu5)); 4.37–4.35 (m, CH(α)(Pro7)); 4.17–4.12 
(m, CH(α)(Leu5), CH(α)(Pro3)); 4.04–4.00 (m, CH(α)(Leu8)); 3.76–3.73 (m, CH(α)(Val)); 
3.60–3.55 (m, 3 H of 2 CH2(δ)(Pro)); 3.40–3.36 (m, 1 H of 2 CH2(δ)(Pro)); 2.21–2.18 (m, 
CH(β)(Val)); 2.12–2.08 (m, 1 H of 2 CH2(β)(Pro)); 2.00–1.95 (m, 1 H of 2 CH2(β)(Pro), 1 H 
of 2 CH2(γ)(Pro)); 1.89–1.85 (m, 1 H of 2 CH2(γ)(Pro)); 1.74–1.68 (m, 2 H of 2 CH2(β)(Pro), 
2 H of 2 CH2(γ)(Pro)); 1.66–1.57 (m, 3 H of 2 CH2(β)(Leu), 2 CH(γ)(Leu)); 1.48–1.44 (m, 1 
H of 2 CH2(β)(Leu)); 1.42, 1.40 (2s, 2 Me of 6 Me(Aib)); 1.38 (s, Me3C, 1 Me of 6 Me(Aib)); 
1.36, 1.35 (2s, 3 Me of 6 Me(Aib)); 1.00, 0.94 (2d, J = 7.0 Hz, 2 Me(Val)); 0.91, 0.87, 0.82, 
0.78 (4d, J = 6.2 Hz, 4 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 173.9 (s, CO(Aib4)); 
172.6 (s, CO(Pro3)); 172.2 (s, CO(Aib2)); 171.7 (s, CO(Leu5), CO(Pro7)); 171.3 (s, 
CO(Leu8)); 170.8 (s, CO(Aib6)); 167.5 (s, CO(Val)); 79.9 (s, Me3C); 63.2 (d, CH(α)(Pro3)); 
60.8 (d, CH(α)(Pro7)); 56.9 (d, CH(α)(Val)); 56.2 (s, C(α)(Aib4)); 56.1 (s, C(α)(Aib2)); 55.6 
(s, C(α)(Aib6)); 51.1 (s, 2 CH(α)(Leu)); 48.0, 47.5 (2t, 2 CH2(δ)(Pro)); 39.6, 39.2 (2t, 2 
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CH2(β)(Leu)); 29.6 (d, CH(β)(Val)); 28.3, 27.6 (2t, 2 CH2(β)Pro)); 27.5 (q, Me3C); 26.4 (q, 1 
Me of 6 Me(Aib)); 25.5 (t, 1 CH2 of 2 CH2(γ)(Pro)); 25.4 (q, 1 Me of 6 Me(Aib)); 25.1 (t, 1 
CH2 of 2 CH2(γ)(Pro)); 24.6, 24.32, 24.29 (3q, 3 Me of 6 Me(Aib)); 24.27, 24.2 (2d, 2 
CH(γ)(Leu)); 23.9 (q, 1 Me of 6 Me(Aib)); 23.0, 22.9, 21.2, 20.6 (4q, 4 Me(Leu)); 18.6, 16.7 
(2q, 2 Me(Val)). ESI-MS: 871 (19, [M+Na]+), 849 (100, [M+H]+). HPLC/MS: tR 13.9 min, 
m/z 849 (100, [M+H]+), 565 (93, [M–(Pro-Leu-OtBu)]+). 
 
4.4.7. Z-Ala-Aib-Pro-Phe-OH (23). Z-ONSu (4.3 mg, 17.3 µmol) and DIPEA (8.1 µl, 47.3 
µmol) were added to a solution of 18 (9.3 mg, 15.8 µmol) in dioxane (2.5 ml) at rt, and the 
solution was stirred at rt for 3 h. The mixture was concentrated, and the crude product was 
purified by prep. HPLC. After lyophilization, Z-Ala-Aib-Pro-Phe-OtBu (HPLC/MS: tR 16.5 
min, m/z 631 (100, [M+Na]+)) (8.5 mg, 89%) was obtained as a colorless powder, which was 
dissolved in CH2Cl2/TFA (1:1, 2 ml) and TIPS (100 µl). The solution was stirred at rt for 1 h, 
then it was concentrated under reduced pressure, and the crude product was purified by prep. 
HPLC. The purified product was lyophilized and yielded 23 (7.5 mg, 97%) as a colorless 
powder. IR (KBr): 3412vs, 3292vs, 3063m, 3032m, 2984s, 2940m, 2876m, 1722vs, 1650vs, 
1535vs, 1499s, 1469m, 1454s, 1411s, 1380m, 1366m, 1340m, 1328m, 1317m, 1282m, 
1243vs, 1215s, 1203s, 1177s, 1116m, 1072m, 1040m, 1028m, 1002w, 977w, 911w, 824w, 
743m, 700s. 1H-NMR ((D6)DMSO, 600 MHz): ca. 13.2–11.2 (br s, COOH); 8.20 (s, 
NH(Aib)); 7.77 (d, J = 8.0 Hz, NH(Phe)); 7.44 (d, J = 7.6 Hz, NH(Ala)); 7.38–7.18 (m, 10 
arom. H); 5.01, 5.06 (AB, J = 12.6 Hz, CH2(carbamate)); 4.37 (ddd, J = 8.4, 8.4, 5.3 Hz, 
CH(α)(Phe)); 4.29–4.27 (m, CH(α)(Pro)); 4.10 (dq, J = 7.2, 7.2 Hz, CH(α)(Ala)); 3.54–3.50, 
3.35–3.31 (2m, CH2(δ)(Pro)); 3.05 (dd, J = 13.9, 5.1 Hz, 1 H of CH2(Phe)); 2.93 (dd, J = 
13.9, 9.2 Hz, 1 H of CH2(Phe)); 1.79–1.73 (m, 1 H of CH2(β)(Pro)); 1.61–1.58 (m, 
CH2(γ)(Pro)); 1.51–1.48 (m, 1 H of CH2(β)(Pro)); 1.30, 1.29 (2s, 2 Me(Aib)); 1.21 (d, J = 7.1 
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Hz, Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 172.6 (s, CO(Phe)); 171.9 (s, CO(Ala)); 
171.7 (s, CO(Pro)); 170.9 (s, CO(Aib)); 155.6 (s, CO(carbamate)); 137.6, 137.0 (2s, 2 arom. 
C); 129.1, 128.2, 128.0, 127.7, 127.6, 126.2 (6d, 10 arom. CH); 65.2 (t, CH2(carbamate)); 
60.9 (d, CH(α)(Pro)); 55.5 (s, C(α)(Aib)); 53.2 (d, CH(α)(Phe)); 49.9 (d, CH(α)(Ala)); 47.2 
(t, CH2(δ)(Pro)); 36.6 (t, CH2(Phe)); 27.8 (t, CH2(β)(Pro)); 25.0 (q, 1 Me of 2 Me(Aib)); 24.9 
(t, CH2(γ)(Pro)); 24.6 (q, 1 Me of 2 Me(Aib)); 17.9 (q, Me(Ala)). ESI-MS: 591 (67, [M+K]+), 
575 (100, [M+Na]+), 553 (44, [M+H]+), 263 (96, [M–(Pro-Phe)–CO]+, [Pro-Phe]+). 
HPLC/MS: tR 14.0 min, m/z 591 (51, [M+K]+), 263 (100, [M–(Pro-Phe)–CO]+, [Pro-Phe]+). 
 
4.4.8. Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OH (24). Z-ONSu (6.0 mg, 24.1 µmol) and 
DIPEA (11.6 µl, 67.8 µmol) were added to a solution of 21 (19.4 mg, 22.6 µmol) in MeCN (5 
ml) at rt, and the solution was stirred at rt for 6 h. Additional Z-ONSu (0.6 mg, 2.3 µmol) and 
DIPEA (3.9 µl, 22.6 µmol) were added, and the solution was stirred at rt for further 2 h. Then, 
the mixture was concentrated, and the crude product was purified by prep. HPLC. After 
lyophilization, Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (HPLC/MS: tR 16.6 min, m/z 880 
(62, [M+H]+)) (13.8 mg, 70%; additionally, 21 (3.8 mg, 20%) was isolated) was obtained as a 
colorless powder, which was dissolved in CH2Cl2/TFA (1:1, 2 ml), H2O (1 drop) and TIPS 
(100 µl). The solution was stirred at rt for 45 min, then it was concentrated under reduced 
pressure, and the crude product was purified by prep. HPLC. The purified product was 
lyophilized and yielded 24 (8.9 mg, 67%) as a colorless powder. IR (KBr): 3418sh, 3308vs, 
3063m, 3033m, 2957m, 2872m, 1660vs, 1532vs, 1469s, 1454s, 1412s, 1387m, 1366m, 1267s, 
1203s, 1176s, 1094s, 1078m, 1028w, 740m, 698m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 
13.2–11.3 (br s, COOH); 8.49 (d, J = 6.0 Hz, NH(Asn)); 8.06 (s, NH(Aib1)); 7.96 (d, J = 7.9 
Hz, NH(Ser)); 7.74 (d, J = 8.5 Hz, NH(Leu)); 7.49 (s, 1 H of CONH2(Asn)); 7.48 (s, 
NH(Aib4)); 7.40–7.26 (m, 10 arom. H); 7.04 (s, 1 H of CONH2(Asn)); 5.08, 5.00 (AB, J = 
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12.4 Hz, CH2(carbamate)); 4.51 (s, OCH2Ph(Ser)); 4.43–4.38 (m, CH(α)(Ser), CH(α)(Pro)); 
4.32–4.29 (m, CH(α)(Asn)); 4.25–4.21 (m, CH(α)(Leu)); 3.75 (dd, J = 9.8, 5.9 Hz, 1 H of 
CH2(β)(Ser)); 3.68 (dd, J = 9.8, 4.2 Hz, 1 H of CH2(β)(Ser)); 3.45–3.42 (m, CH2(δ)(Pro)); 
2.67–2.63, 2.57–2.54 (2m, CH2(β)(Asn)); 1.90–1.86, 1.75–1.56 (2m, CH2(β)(Pro), 
CH2(γ)(Pro), CH2(β)(Leu), CH(γ)(Leu)); 1.36 (s, 1 Me of 2 Me(Aib1)); 1.35, 1.332 (2s, 2 
Me(Aib4)); 1.325 (s, 1 Me of 2 Me(Aib1)); 0.81, 0.74 (2d, J = 6.3 Hz, 2 Me(Leu)). 13C-NMR 
((D6)DMSO, 150 MHz): 175.3 (s, CO(Aib1)); 172.1 (s, CONH2(Asn)); 172.0 (s, CO(Pro)); 
171.4 (s, CO(Ser)); 171.2 (s, CO(Leu)); 170.9 (s, CO(Asn)); 170.8 (s, CO(Aib4)); 156.2 (s, 
CO(carbamate)); 138.1 (s, arom. C(Bn)); 136.4 (s, arom. C(Z)); 128.4, 128.2, 128.0, 127.7, 
127.5, 127.4 (6d, 10 arom. CH); 72.2 (t, OCH2Ph(Ser)); 69.4 (t, CH2(β)(Ser)); 65.7 (t, 
CH2(carbamate)); 60.7 (d, CH(α)(Pro)); 56.1 (s, C(α)(Aib1)); 55.8 (s, C(α)(Aib4)); 52.4 (d, 
CH(α)(Ser)); 51.6 (d, CH(α)(Asn)); 50.9 (d, CH(α)(Leu)); 47.5 (t, CH2(δ)(Pro)); 39.4 (t, 
CH2(β)(Leu)); 35.1 (t, CH2(β)(Asn)); 27.9 (t, CH2(β)(Pro)); 26.1 (q, 1 Me of 2 Me(Aib1)); 
25.1 (q, 1 Me of 2 Me(Aib4)); 25.0 (t, CH2(γ)(Pro)); 24.8 (q, 1 Me of 2 Me(Aib4)); 24.0 (d, 
CH(γ)(Leu)); 23.9 (q, 1 Me of 2 Me(Aib1)); 23.1, 20.7 (2q, 2 Me(Leu)). ESI-MS: 868 (45, 
[M–H+2Na]+), 846 (100, [M+Na]+). HPLC/MS: tR 15.6 min, m/z 824 (11, [M+H]+), 532 (100, 
[M–(Pro-Ser(OBn)-OtBu)]+), 447 (40, [M–(Aib-Pro-Ser(OBn)-OtBu)]+). 
 
4.4.9. Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (25). 
HOBt, TBTU, and DIPEA were taken from stock-solutions. HOBt (1.7 mg, 11.1 µmol), 
TBTU (3.5 mg, 11.0 µmol), DIPEA (5.4 µl, 31.3 µmol) and 22 (10.6 mg, 11.0 µmol) were 
added to a solution of 24 (8.6 mg, 10.4 µmol) in CH2Cl2/DMF (1:1, 3 ml). The mixture was 
stirred at rt for 4 h, the solvent was evaporated under reduced pressure, and the crude product 
was purified by prep. HPLC. After lyophilization, 25 (12.5 mg, 73%) was obtained as a 
colorless powder. IR (KBr): 3435sh, 3306s, 2958m, 2872w, 1648vs, 1623vs, 1536vs, 1470s, 
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1454m, 1412s, 1385m, 1366m, 1269m, 1203m, 1172s, 1152m, 1094w, 1028w, 740w, 698w. 
1H-NMR ((D6)DMSO, 600 MHz): 8.57 (d, J = 5.5 Hz, NH(Asn)); 8.11 (s, 1 NH of 5 
NH(Aib)); 7.90 (d, J = 6.7 Hz, NH(Ser)); 7.82 (d, J = 7.7 Hz, 1 NH of 3 NH(Leu)); 7.82, 7.79 
(2s, 2 NH of 5 NH(Aib)); 7.74 (d, J = 7.7 Hz, 1 NH of 3 NH(Leu)); 7.55, 7.54 (2s, 2 NH of 5 
NH(Aib)); 7.53 (s, 1 H of CONH2(Asn)); 7.39–7.30, 7.27–7.24 (2m, 10 arom. H, 1 NH of 3  
NH(Leu), NH(Val)); 7.07 (s, 1 H of CONH2(Asn)); 5.07, 5.00 (AB, J = 12.3 Hz, 
CH2(carbamate)); 4.55, 4.51 (AB, J = 11.9 Hz, OCH2Ph(Ser)); 4.38–4.36 (m, 1 H of 3 
CH(α)(Pro)); 4.33–4.26 (m, CH(α)(Ser), CH(α)(Asn), 1 H of 3 CH(α)(Leu), 1 H of 3 
CH(α)(Pro)); 4.19–4.14 (m, 1 H of 3 CH(α)(Leu), CH(α)(Val)); 4.08 (dd, J = 8.4, 8.4 Hz, 1 H 
of 3 CH(α)(Pro)); 4.04–4.00 (m, 1 H of 3 CH(α)(Leu)); 3.86–3.83 (m, 1 H of CH2(β)(Ser)); 
3.77–3.68 (m, 1 H of CH2(β)(Ser), 2 H of 3 CH2(δ)(Pro)); 3.65–3.61, 3.52–3.48, 3.38–3.34, 
3.30–3.25 (4m, 4 H of 3 CH2(δ)(Pro)); 2.68–2.64, 2.60–2.56 (2m, CH2(β)(Asn)); 2.24–2.19 
(m, 2 H of 3 CH2(β)(Pro)); 2.09 (dsept., J = 6.8, 6.8 Hz, CH(β)(Val)); 2.01–1.98 (m, 1 H of 3 
CH2(β)(Pro)); 1.93–1.83 (m, 4 H of 3 CH2(γ)(Pro)); 1.74–1.57 (m, 3 CH(γ)(Leu), 4 H of 3 
CH2(β)(Leu), 3 H of 3 CH2(β)(Pro), 2 H of 3 CH2(γ)(Pro)); 1.54–1.51 (m, 1 H of 3 
CH2(β)(Leu)); 1.48 (s, 1 Me of 10 Me(Aib)); ca. 1.44 (m, 1 H of 3 CH2(β)(Leu)); 1.43, 1.42, 
1.38, 1.37, 1.364, 1.358, 1.34 (7s, 9 Me of 10 Me(Aib), Me3C); 0.91 (d, J = 6.4 Hz, 1 Me of 6 
Me(Leu)); 0.87, 0.83 (2d, J = 6.8 Hz, 2 Me(Val)); 0.82 (d, J = 6.4 Hz, 2 Me of 6 Me(Leu)); 
0.749, 0.745 (2d, J = 6.0 Hz, 2 Me of 6 Me(Leu)); 0.63 (d, J = 6.2 Hz, 1 Me of 6 Me(Leu)). 
13C-NMR ((D6)DMSO, 150 MHz): 175.7, 174.2, 173.0. 172.8, 172.74, 172.70, 172.6, 171.90, 
171.86, 171.6, 171.3, 171.2, 171.1, 170.9, 169.6 (15s, 15 CO); 156.2 (s, CO(carbamate)); 
137.9 (s, arom. C of CH2Ph(Ser)); 136.2 (s, arom. C(Z)); 128.3, 128.1, 127.9, 127.6, 127.4, 
127.2 (6d, 10 arom. CH); 79.8 (s, Me3C); 72.0 (t, OCH2Ph(Ser)); 68.6 (t, CH2(β)(Ser)); 65.8 
(t, CH2(carbamate)); 63.9, 62.9, 60.8 (3d, 3 CH(α)(Pro)); 58.3 (d, CH(α)(Val)); 56.1, 56.0, 
55.9, 55.8, 55.6 (5s, 5 C(α)(Aib)); 55.4, 51.9 (2d, CH(α)(Asn), CH(α)(Ser)); 51.1, 51.0 (2d, 3 
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CH(α)(Leu)); 48.3, 48.2, 47.6 (3t, 3 CH2(δ)(Pro)); 39.5, 39.1, 39.1 (3t, 3 CH2(β)(Leu)); 34.9 
(t, CH2(β)(Asn)); 29.6 (d, CH(β)(Val)); 28.4, 28.3, 28.1 (3t, 3 CH2(β)(Pro)); 27.5 (q, Me3C); 
26.5, 26.0, 25.7 (3q, 3 Me of 10 Me(Aib)); 25.6 (t, 1 CH2 of 3 CH2(γ)(Pro)); 25.5 (q, 1 Me of 
10 Me(Aib)); 25.4 (t, 1 CH2 of 3 CH2(γ)(Pro)); 25.3 (q, 1 Me of 10 Me(Aib)); 25.1 (t, 1 CH2 
of 3 CH2(γ)(Pro)); 24.2 (q,d, 1 Me of 10 Me(Aib), 2 CH of 3 CH(γ)(Leu)); 23.81 (q, 1 Me of 
10 Me(Aib)); 23.76 (d, 1 CH of 3 CH(γ)(Leu)); 23.3 (q, 2 Me of 10 Me(Aib)); 23.1 (q, 1 Me 
of 10 Me(Aib)); 23.0, 22.93, 22.89, 21.1, 20.3, 20.2 (6q, 6 Me(Leu)); 18.8, 17.9 (2q, 2 
Me(Val)). ESI-MS: 1693 (17, [M+K]+), 1677 (85, [M+Na]+). HPLC/MS: tR 18.1 min, m/z 
1676 (2, [M+H]+), 846 (100), 819 (35). 
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Table 
 
Table 1. Peptides synthesized by means of the ‘azirine/oxazolone method’ on solid phase. 
Sequence Description Yield [%] a) 
H-Ala-Aib-Phe-OtBu (15) model peptide 33 
H-Ala-Aib-Pro-Phe-OtBu (18) model peptide 35 
H-Val-Aib-Gly-Aib-Aib-Pro-Leu-OtBu (20) A8–A14 of Trichovirin Ia 42 
H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu (21) A1–A6 of Trichovirin I 1B 34 
H-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu (22) A7–A14 of Trichovirin I 1B 34 
a) based on resin loading, after prep. HPLC. 
 
 
 
 
Captions 
Table 1. Peptides synthesized by means of the ‘azirine/oxazolone method’ on solid phase. 
Scheme 1. 
Scheme 2. 
Scheme 3. 
Scheme 4. 
Scheme 5. 
Scheme 6. 
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Formula Collection 
 
 
R1
N
N
Ph
1a   R1 = R2 = Me
1b   R1 – R2 = –(CH2)4–
1c   R1 – R2 = –(CH2)2O(CH2)2–
1d   R1 = Me, R2 = PhCH2
R2
N
N
O OR
2a   R = Me
2b   R = CH2CHCH2
2c   R = PhCOCH2
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Schemes 
Scheme 1 
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Scheme 2 
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Scheme 3 
 
 
13  R = N(Me)Ph
14  R = OH
1) COCl2 (1.9M in PhMe), THF
2) H-Ala-OtBu · HCl, DIPEA, CH2Cl2
11  R = OtBu
12  R = OH
10
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HCl (3M), THF/ H2O
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Scheme 4 
 
 
1) COCl2 (1.9M in PhMe), THF
2) H-Ala-OtBu · HCl, DIPEA, CH2Cl2
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Scheme 5 
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Scheme 6 
 
 
H-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OtBu Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-OH
1. Z-ONSu, DIPEA,
1. dioxane, rt
2. TFA, CH2Cl2,
2. TIPS, H2O, rt21 24
Z-Aib-Asn-Leu-Aib-Pro-Ser(OBn)-Val-Aib-Pro-Aib-Leu-Aib-Pro-Leu-OtBu
25
22, TBTU, HOBt,
DIPEA, CH2Cl2,
DMF, rt
